IMA Active is now ready for the paradigm shift in pharmaceutical manufacturing and taking the lead in the future of pharmaceutical technologies for OSD forms.
IMA Active’s belief in and knowledge of Continuous Manufacturing have grown stronger thanks to intensive R&D work carried out on two fronts.
Important contribution for reducing costs includes smaller equipment and fewer manufacturing steps, with consequent saving for installation, validation and maintenance. In addition, rapid development, improved yields, less personnel achieve overall estimated cost reduction range from 30% to 50%, with impact on drugs affordability as well.
Based on more than 50 years’ process experience, IMA Active would like to involve you and rapidly illustrate the benefits of continuous processing. IMA Active contributes to making Continuous Manufacturing available for all and not just for a small elite of pharmaceutical manufacturers.
CDC is a very lean, efficient and flexible tablet-manufacturing technology that, in combination with PAT, allows easy adoption of a QbD approach.
CDC provides excellent operation performance; the system is designed to achieve a state of control very quickly and avoid any waste during startup and shutdown phases.
Continuous coating is a further manufacturing step that can be considered either straight inline or as a separate and subsequent step with regard to CDC.
CROMA continuous coater is IMA Active’s novel technology for a fast and truly continuous process. Designed to be modular to manage a range of tablets throughput and a range of coating weight gain.
All the benefits of Continuous Manufacturing are gained by reducing the overall complexity of the product lifecycle and by decreasing the number of process variables.
Hardshell capsules are the preferred choice for packing a simple blend of powders with no other intermediate steps.
IMA Active has been cultivating its own knowledge and is ready to welcome the demand for innovation, working together with companies and stakeholders to design the future of pharmaceutical manufacturing.
Bernhardt L. Trout is Professor of Chemical Engineering at MIT and Director of Novartis-MIT Center for Continuous Manufacturing. His research focuses on the development of advanced manufacturing processes and rational tools for formulation and product design.
Moheb M. Nasr managed the CDER Pharmaceutical Analysis Program at the US FDA for four years and had the lead of the CDER/FDA CMC Regulatory Program for more than eight years. He also worked for GSK as VP Global CMC Strategy. In 2018 he started his own consultancy business.
Guia Bertuzzi is Product Manager at IMA Active division since 2005. She has been working in mixing, granulation and powders handling systems for more than 20 years. She is expert in pharmaceutical engineering and process for Active Pharmaceutical Ingredients and Oral Solid Dosage forms.
Salvatore Mascia is the Founder and CEO of CONTINUUS Pharmaceuticals. He was the former Strategic Project Manager at the Novartis-MIT Center for Continuous Manufacturing, where he led the integration of the first end-to-end Continuous Manufacturing process for pharmaceuticals.
Keirnan LaMarche is Senior Principal Scientist at Patheon. He is an expert in solid dosage form design, continuous manufacturing, and he received his PhD in chemical Engineering from Rutgers University in 2008. He gained 10 years of experience in solid dosage form development at Bristol-Myers Squibb.
Giustino Di Pretoro is Associate Director at Janssen Pharmaceutica, a Johnson & Johnson Company. He is a subject matter expert and drug product development lead for Continuous Manufacturing, and coordinator for a series of academic collaborations within the field of continuous.
Frank Streil is Director Technical and Scientific Affairs at Teva/RATIOPHARM. His main interests and experience are in the field of process development and validation as well as in new technologies, PAT and Continuous Manufacturing.
Alan Johnston is Senior Life Sciences Consultant at Emerson’s Global consultancy team. He has spent a majority of his career in the Life Sciences industry with a broad range of technical and business experience across production, automation and digitalization including Primary, Secondary and Vaccine manufacture. He has previously held senior technical roles at Siemens, Novartis Vaccines and GSK.